Fig. 2: The immunomodulatory effect of PIC in vitro. | Nature Communications

Fig. 2: The immunomodulatory effect of PIC in vitro.

From: Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade

Fig. 2

a Scheme for the RT-qPCR studies of B78 cells. The relative mRNA expression of b Ifnβ1 and c Pd-l1 in B78 cells at day 7 after initiation of indicated treatments. PIC: 4.67 μg/mL; RT: 12 Gy. (n = 3 biologically independent samples). d Scheme for the study of the macrophage polarization effect of PIC on BMDMs. The MFI of CD206 and CD163 on CD11b+F4/80+ BMDMs at day 1 and day 4 after the cells were treated with e PIC and f RT + PIC. g The ratios of CD80 MFI to CD206 MFI on CD11b+F4/80+ BMDMs at day 1 and day 4 after indicated treatment. h The ratios of M1: M2 macrophage in CD11b+F4/80+ BMDMs at day 4 after indicated treatment. M1-like: CD80+CD206−; M2-like: CD206+CD80−. PIC: 4.67 μg/mL; RT: 12 Gy. (n = 4 biologically independent samples). i The MFI of CD80 and CD86 on CD317+CD11c+ pDCs after indicated treatments. PIC: 4.67 μg/mL; CpG: 0.5 μg/mL. (n = 3 biologically independent samples). j The percentage of FITC-Ova positive cells among CD11c+ DCs at 24 h after treatment. FITC-Ova: 1.67 μg/mL; PIC: 4.67 μg/mL. (n = 4 biologically independent samples). DCs were enriched from the splenocytes collected from Flt3L treated C57BL/6 mice. Statistical significance was calculated via one-way ANOVA test in b, c and e–j, and data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Source data are provided in Source Data file.

Back to article page